Authors : Jegathishan E.; Rakchitha; Ramya; Ranjith; Roopikaashree; Dr. Kannan S.; Dr. Sangameswaran B.

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/4vweynfw

Scribd : https://tinyurl.com/59fch57p

DOI : https://doi.org/10.38124/ijisrt/26May510

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: When 2 or more drugs given together may produces either pharmacokinetic or pharmacodynamic drug-drug interaction at any age.  Aim & Objective: The observational study that aimed to assess the prevalence of potential drug-drug interactions (DDIs), identify highrisk departments, evaluate the impact of clinical pharmacist interventions on managing these interactions, and determine the rate of physician acceptance of recommendations in a multi-specialty hospital.  Material & Methods: A prospective, observational, and interventional study was conducted over a 6-month period, analysing patient prescriptions across various departments [e.g., cardiology, general medicine, ICU]. Data were assessed using drug databases [e.g., Lexicomp, DrugBank, and Medscape] to classify DDIs based on the severity [Major, Moderate, and Minor].  Results: DDI Prevalence: A high prevalence of DDI was observed, with studies reporting that 43.43% to over 78% of patients in hospital settings had at least one potential DDI. Severity & Type: The majority of interactions were moderate in severity. Impact & Interventions: Pharmacists interventions, including dose adjustments, discontinuation of drugs, and alternative therapy recommendations, significantly reduced the risk of adverse drug reaction. Polypharmacy [a greater number of medications] and elderly patients were strongly associated with the higher incidence of DDI.  Conclusion: The study concludes that the potential drug-drug interactions are common in multi-specialty hospitals. Timely pharmacist interventions are effective in identifying, preventing, and managing these interactions, that leads to enhancing patient safety, improving quality of care, and reducing the incidence of adverse drug events.

Keywords : Drug- Drug Interaction, Pharmacists Interventions, Pharmacokinetic, Pharmacodynamic, Polypharmacy, Patient Safety, Clinical Pharmacists.

References :

1. Baxter K, Preston CL, editors. Stockley’s Drug Interactions. 12^th ed. London: Pharmaceutical Press; 2022.
2. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in Elderly. Expert Opinion Drug Saf. 2014; 13(1):57-65.
3. Wang J, Manias E, Toouli G. The role of clinical pharmacists in preventing drug-Drug interactions.
4. Siller-Matula JM, Spiel AO, Lang IM. Kreiner G, Christ G, Jilma B. Effects of proton pump inhibitors on clopidogrel efficacy. J Thromb Haemost. 2010; 8(12): 2624 – 2641.
5. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and non- steroidal anti-inflammatory drugs and the risk of acute kidney injury.BMJ.2013;346: e8525.
6. Aparasu RR, Hegge M, et al., Impacts of pharmacist interventions on preventing clinically significant drug-drug interaction in hospitalized patients. J Clin pharm Ther. 2007; 32(3):273-280.
7. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. pharmacotherapy. 2007; 27(4):481-493.
8. Katzung BG. Basic and clinical pharmacology.
9. Shafiekhani M, Moosavi N, Firouzabadi D, Namazi S. Journal of Research in Pharmacy Practice. 2019;8(3): 143-148.
10. Dagnew SB, Mekonnen GB, Zeleke EG, et.al., Clinical pharmacist intervention on drug-related problems among elderly patients admitted to medical wards: A multicenter prospective observational study. 2022
11. ADA Guidelines.
12. Brunton LL, et.al., Goodman and Gilmans’s pharmacology.
13. GINA Guidelines.
14. Wishart DS, Knoc C, Guo AC, Cheng D, Shrivastava S, Tzur D, et.al., DrugBank: a Acknowledgement for drugs, drug actions and drug targets. 2008;36(Database issue):D901-D906.